Analysis of clinical presentation and genetic characteristics of malignant infantile osteopetrosis

Objective: To investigate the clinical presentation and genetic characteristics of malignant infantile osteopetrosis. Methods: This was a retrospective case study. Thirty-seven children with malignant infantile osteopetrosis admitted into Beijing Children's Hospital from January 2013 to Septemb...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 61(2023), 11 vom: 02. Nov., Seite 1038-1042
1. Verfasser: Wei, A (VerfasserIn)
Weitere Verfasser: Zhu, G H, Qin, M Q, Jia, C G, Wang, B, Yang, J, Luo, Y H, Jing, Y F, Yan, Y, Zhou, X, Wang, T Y
Format: Online-Aufsatz
Sprache:Chinese
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:English Abstract Journal Article Phosphorus 27YLU75U4W Chloride Channels TCIRG1 protein, human Vacuolar Proton-Translocating ATPases EC 3.6.1.- CLCN7 protein, human
LEADER 01000naa a22002652 4500
001 NLM363913564
003 DE-627
005 20231226094340.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||chi c
024 7 |a 10.3760/cma.j.cn112140-20230822-00124  |2 doi 
028 5 2 |a pubmed24n1212.xml 
035 |a (DE-627)NLM363913564 
035 |a (NLM)37899344 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Wei, A  |e verfasserin  |4 aut 
245 1 0 |a Analysis of clinical presentation and genetic characteristics of malignant infantile osteopetrosis 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 31.10.2023 
500 |a Date Revised 31.10.2023 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Objective: To investigate the clinical presentation and genetic characteristics of malignant infantile osteopetrosis. Methods: This was a retrospective case study. Thirty-seven children with malignant infantile osteopetrosis admitted into Beijing Children's Hospital from January 2013 to September 2022 were enrolled in this study. According to the gene mutations, the patients were divided into the CLCN7 group and the TCIRG1 group. Clinical characteristics, laboratory tests, and prognosis were compared between two groups. Wilcoxon test or Fisher exact test were used in inter-group comparison. The survival rate was estimated with the Kaplan-Meier method and the Log-Rank test was used to compare the difference in survival between groups. Results: Among the 37 cases, there were 22 males and 15 females. The age of diagnosis was 0.5 (0.2, 1.0) year. There were 13 patients (35%) and 24 patients (65%) with mutations in CLCN7 and TCIRGI gene respectively. Patients in the CLCN7 group had an older age of diagnosis than those in the TCIRGI group (1.2 (0.4, 3.6) vs. 0.4 (0.2, 0.6) years, Z=-2.60, P=0.008). The levels of serum phosphorus (1.7 (1.3, 1.8) vs. 1.1 (0.8, 1.6) mmol/L, Z=-2.59, P=0.010), creatine kinase isoenzyme (CK-MB) (457 (143, 610) vs. 56 (37, 82) U/L, Z=-3.38, P=0.001) and the level of neutrophils (14.0 (9.9, 18.1) vs. 9.2 (6.7, 11.1) ×109/L, Z=-2.07, P=0.039) at diagnosis were higher in the CLCN7 group than that in the TCIRG1 group. However, the level of D-dimer in the CLCN7 group was lower than that in the TCIRGI group (2.7 (1.0, 3.1) vs. 6.3 (2.5, 9.7) μg/L, Z=2.83, P=0.005). After hematopoietic stem cell transplantation, there was no significant difference in 5-year overall survival rate between the two groups (92.3%±7.4% vs. 83.3%±7.6%, χ²=0.56, P=0.456). Conclusions: TCIRGI gene mutations are more common in children with osteopetrosis. Children with TCIRGI gene mutations have younger age, lower levels of phosphorus, CK-MB, and neutrophils and higher level of D-dimer at the onset. After hematopoietic stem cell transplantation, patients with CLCN7 or TCIRGI gene mutations have similar prognosis 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a Phosphorus  |2 NLM 
650 7 |a 27YLU75U4W  |2 NLM 
650 7 |a Chloride Channels  |2 NLM 
650 7 |a TCIRG1 protein, human  |2 NLM 
650 7 |a Vacuolar Proton-Translocating ATPases  |2 NLM 
650 7 |a EC 3.6.1.-  |2 NLM 
650 7 |a CLCN7 protein, human  |2 NLM 
700 1 |a Zhu, G H  |e verfasserin  |4 aut 
700 1 |a Qin, M Q  |e verfasserin  |4 aut 
700 1 |a Jia, C G  |e verfasserin  |4 aut 
700 1 |a Wang, B  |e verfasserin  |4 aut 
700 1 |a Yang, J  |e verfasserin  |4 aut 
700 1 |a Luo, Y H  |e verfasserin  |4 aut 
700 1 |a Jing, Y F  |e verfasserin  |4 aut 
700 1 |a Yan, Y  |e verfasserin  |4 aut 
700 1 |a Zhou, X  |e verfasserin  |4 aut 
700 1 |a Wang, T Y  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 61(2023), 11 vom: 02. Nov., Seite 1038-1042  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:61  |g year:2023  |g number:11  |g day:02  |g month:11  |g pages:1038-1042 
856 4 0 |u http://dx.doi.org/10.3760/cma.j.cn112140-20230822-00124  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 61  |j 2023  |e 11  |b 02  |c 11  |h 1038-1042